Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
IGC 
India Globalization Capital Inc (IGC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: IGC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.88
1 Year Target Price $3.88
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 22.58% | Avg. Invested days 65 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.62M USD | Price to earnings Ratio - | 1Y Target Price 3.88 |
Price to earnings Ratio - | 1Y Target Price 3.88 | ||
Volume (30-day avg) 2 | Beta 1.48 | 52 Weeks Range 0.25 - 0.50 | Updated Date 07/7/2025 |
52 Weeks Range 0.25 - 0.50 | Updated Date 07/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-06-30 | When - | Estimate -0.02 | Actual -0.02 |
Profitability
Profit Margin - | Operating Margin (TTM) -443.03% |
Management Effectiveness
Return on Assets (TTM) -49.91% | Return on Equity (TTM) -104.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 25210204 | Price to Sales(TTM) 20.94 |
Enterprise Value 25210204 | Price to Sales(TTM) 20.94 | ||
Enterprise Value to Revenue 19.83 | Enterprise Value to EBITDA -2.54 | Shares Outstanding 83891600 | Shares Floating 74949582 |
Shares Outstanding 83891600 | Shares Floating 74949582 | ||
Percent Insiders 9.16 | Percent Institutions 19.89 |
About India Globalization Capital Inc
Exchange NYSE MKT | Headquaters Potomac, MD, United States | ||
IPO Launch date 2006-04-13 | President, CEO & Director Mr. Ram Mukunda | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://igcpharma.com |
Full time employees 70 | Website https://igcpharma.com | ||
IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease in India, the United States, and Colombia. The company's lead product is IGC-AD1, which is in Phase 2 clinical trial for the treatment of agitation in dementia due to Alzheimer's; and TGR-63, IGC-M3, and LMP that are in pre-clinical stage for the treatment of Alzheimer's disease. It also develops IGC-1A and IGC-1C which are in pre-clinical stage for the treatment of metabolic disorders and Alzheimer's disease. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.